LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 472

Search options

  1. Article ; Online: Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.

    Trock, Bruce J / Karnes, R Jeffrey

    European urology

    2017  Volume 72, Issue 6, Page(s) e158–e159

    MeSH term(s) Genomics ; Humans ; Male ; Prostatic Neoplasms
    Language English
    Publishing date 2017-05-31
    Publishing country Switzerland
    Document type Letter ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2017.05.030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Editorial Comment.

    Karnes, R Jeffrey

    The Journal of urology

    2022  Volume 208, Issue 4, Page(s) 844–845

    Language English
    Publishing date 2022-07-15
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1097/JU.0000000000002803.02
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Editorial Comment.

    Karnes, R Jeffrey

    The Journal of urology

    2021  Volume 207, Issue 3, Page(s) 591

    Language English
    Publishing date 2021-12-15
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1097/JU.0000000000002256.01
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Current evidence on local therapy in oligometastatic prostate cancer.

    Basourakos, Spyridon P / Henning, Grant / Karnes, R Jeffrey

    Current opinion in urology

    2024  Volume 34, Issue 3, Page(s) 198–203

    Abstract: Purpose of review: Metastatic prostate cancer (PCa) continues to be an invariably fatal condition. While historically, de-novo metastatic PCa was primarily treated with androgen deprivation therapy (ADT) and systemic therapy, there is a growing trend ... ...

    Abstract Purpose of review: Metastatic prostate cancer (PCa) continues to be an invariably fatal condition. While historically, de-novo metastatic PCa was primarily treated with androgen deprivation therapy (ADT) and systemic therapy, there is a growing trend toward incorporating local treatments in the early management of the disease. This is particularly applicable to men with oligometastatic PCa (OMPC), which represents an 'intermediate phase' between localized and disseminated metastatic disease. Local treatment offers an opportunity for disease control before it progresses to a more advanced stage. This review discussed the current evidence for local treatment options for OMPC.
    Recent findings: Currently, it has been suggested that men with OMPC may have a more indolent course and, therefore, favorable outcomes may be observed with metastasis-directed therapy (MDT). This review will not address the role of MDT to patients with OMPC but will focus on local treatments of the primary disease. The three main forms of local therapy employed for OMPC are cryotherapy, radiation therapy, and cytoreductive prostatectomy (CRP). Whole gland cryotherapy, either with ADT or with ADT and systemic chemotherapy, has shown some limited promising results. Radiation therapy combined with ADT has also demonstrated improvements in progression-free survival in clinical trials (primarily STAMPEDE Arm G and HORRAD). CRP often combined with ADT has emerged as a potential strategy for managing OMPC, with promising findings primarily from retrospective studies. Currently, several randomized controlled trials are underway to further investigate the role of CRP in the oligometastatic setting.
    Summary: OMPC has become a unique category of disease with specific therapeutic implications. Lack of robust clinical data renders treatment selection controversial. Further studies with long follow up are necessary to identify men with oligometastatic disease who will benefit from local treatment.
    MeSH term(s) Male ; Humans ; Prostatic Neoplasms/pathology ; Androgen Antagonists/therapeutic use ; Retrospective Studies ; Treatment Outcome ; Prostatectomy/methods
    Chemical Substances Androgen Antagonists
    Language English
    Publishing date 2024-02-01
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1091792-5
    ISSN 1473-6586 ; 0963-0643
    ISSN (online) 1473-6586
    ISSN 0963-0643
    DOI 10.1097/MOU.0000000000001161
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Salvage radical prostatectomy.

    Nabavizadeh, Reza / Karnes, R Jeffrey

    Current opinion in urology

    2022  Volume 33, Issue 2, Page(s) 163–167

    Abstract: Purpose of review: Salvage radical prostatectomy (sRP) is underutilized because of fear of historical high rates of peri-operative morbidities. However, there has been significant improvements in complication rates as well as oncologic outcomes in the ... ...

    Abstract Purpose of review: Salvage radical prostatectomy (sRP) is underutilized because of fear of historical high rates of peri-operative morbidities. However, there has been significant improvements in complication rates as well as oncologic outcomes in the recent years.
    Recent findings: Complication rates have significantly declined for both open and robotic approach in the past decade. Rectal injury is now reported around 2%, which is down from 30% in the historic series. Similarly, the current risk of major vascular injury is low. About 75% of patients report social continence (up to one pad per day). However, erectile function recovery remains poor and patients should be counselled accordingly. Long-term durable oncologic response is achievable with 10-year recurrence-free survival reported in about 40-50% of well selected patients.
    Summary: Recent improvements in oncologic and peri-operative outcomes make sRP a desirable option for local control. sRP treats the whole gland as opposed to focal therapies and allows for pelvic lymph node dissection and removal of seminal vesicles, which can be sanctuary site of disease. In experienced hands, regardless of the surgical approach, sRP can achieve a durable response resulting in delaying or avoiding androgen deprivation therapy and its associated morbidities.
    MeSH term(s) Male ; Humans ; Treatment Outcome ; Seminal Vesicles/pathology ; Androgen Antagonists ; Prostatic Neoplasms/surgery ; Prostatectomy/adverse effects ; Prostatectomy/methods ; Salvage Therapy/methods ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Recurrence, Local/pathology
    Chemical Substances Androgen Antagonists
    Language English
    Publishing date 2022-12-29
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1091792-5
    ISSN 1473-6586 ; 0963-0643
    ISSN (online) 1473-6586
    ISSN 0963-0643
    DOI 10.1097/MOU.0000000000001074
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Editorial: Salvage therapy in uro-oncology.

    Heidenreich, Axel / Karnes, R Jeffrey

    Current opinion in urology

    2021  Volume 31, Issue 3, Page(s) 177

    MeSH term(s) Humans ; Medical Oncology ; Salvage Therapy ; Urology
    Language English
    Publishing date 2021-03-25
    Publishing country United States
    Document type Editorial
    ZDB-ID 1091792-5
    ISSN 1473-6586 ; 0963-0643
    ISSN (online) 1473-6586
    ISSN 0963-0643
    DOI 10.1097/MOU.0000000000000876
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Addressing the need for more therapeutic options in neuroendocrine prostate cancer.

    Kemble, Jayson / Kwon, Eugene D / Karnes, R Jeffrey

    Expert review of anticancer therapy

    2023  Volume 23, Issue 2, Page(s) 177–185

    Abstract: Introduction: Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer frequently seen after prolonged treatment of castration resistant prostate cancer (CRPC). NEPC has become increasingly prevalent over the last 20 years, with a ... ...

    Abstract Introduction: Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer frequently seen after prolonged treatment of castration resistant prostate cancer (CRPC). NEPC has become increasingly prevalent over the last 20 years, with a poor prognosis caused by a late diagnosis and limited treatment options. Recent advances in PET/CT imaging and targeted radioimmunotherapy are promising, but more research into additional treatment options is needed.
    Areas covered: The aim of this review is to analyze the current imaging and treatment options for NEPC, and to highlight future potential treatment strategies. A Pubmed search for 'Neuroendocrine Prostate Cancer' was performed and relevant articles were reviewed.
    Expert opinion: The recent FDA approval and success of 177 PSMA Lutetium in CRPC is promising, as 177 Lutetium could potentially be paired with a NEPC specific biomarker for targeted therapy. Recent laboratory studies pairing DLL3, which is overexpressed in NEPC, with 177 Lutetium and new PET agents have showed good efficacy in identifying and treating NEPC. The success of future development of NEPC therapies may depend on the availability of 177 Lutetium, as current supplies are limited. Further research into additional imaging and treatment options for NEPC is warranted.
    MeSH term(s) Male ; Humans ; Prostatic Neoplasms, Castration-Resistant ; Lutetium ; Positron Emission Tomography Computed Tomography ; Prostatic Neoplasms ; Radioisotopes ; Carcinoma, Neuroendocrine/therapy ; Membrane Proteins ; Intracellular Signaling Peptides and Proteins
    Chemical Substances Lutetium-177 (BRH40Y9V1Q) ; Lutetium (5H0DOZ21UJ) ; Radioisotopes ; DLL3 protein, human ; Membrane Proteins ; Intracellular Signaling Peptides and Proteins
    Language English
    Publishing date 2023-02-03
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2023.2173174
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.

    Sharma, Vidit / Karnes, R Jeffrey

    European urology

    2021  Volume 80, Issue 3, Page(s) 385

    MeSH term(s) Humans ; Male ; Positron Emission Tomography Computed Tomography ; Prospective Studies ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/radiotherapy
    Language English
    Publishing date 2021-06-24
    Publishing country Switzerland
    Document type Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2021.05.037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Neoadjuvant chemotherapy in bladder cancer: not a matter on how much but on who it is effective.

    Motterle, Giovanni / Karnes, R Jeffrey

    Translational andrology and urology

    2020  Volume 8, Issue Suppl 5, Page(s) S480–S481

    Language English
    Publishing date 2020-01-23
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2851630-8
    ISSN 2223-4691 ; 2223-4691 ; 2223-4683
    ISSN (online) 2223-4691
    ISSN 2223-4691 ; 2223-4683
    DOI 10.21037/tau.2019.09.39
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: "To Serve and ProtecT": Has the Pendulum Swung Too Far Towards Surveillance?

    Sharma, Vidit / Jeffrey Karnes, R

    European urology

    2019  Volume 77, Issue 3, Page(s) 331–332

    MeSH term(s) Disease Progression ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Iatrogenic Disease ; Male ; Prostatic Neoplasms
    Language English
    Publishing date 2019-12-20
    Publishing country Switzerland
    Document type Editorial ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2019.12.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top